- In May 2023, Coherus BioSciences announced the commercial availability of its single-dose (6mg/0.6mL) prefilled autoinjector for UDENYCA in the United States. This device offers a streamlined design, enabling administration in less than 10 seconds, suitable for both in-office and at-home settings
- Researchers have developed a new type of contraceptive implant that can be administered via injection and self-assembles in the body, potentially offering long-term drug delivery without the need for surgical procedures. While not yet tested in humans, proof-of-concept experiments in rats showed that the drug release could be sustained for at least 97 days. This approach could also be applicable for other treatments such as HIV, chronic pain, and metabolic diseases.
- The integration of smart technologies is a significant advancement in the on-body drug delivery devices industry. Many current wearable injectors now include connectivity features that enable them to communicate with smartphones and other digital health systems. This connectivity allows for real-time monitoring of medication adherence and patient health parameters, enhancing treatment outcomes and patient engagement.
